Research programme: protein therapeutics - Ansun Biopharma

Drug Profile

Research programme: protein therapeutics - Ansun Biopharma

Alternative Names: ANSX109/142; ANSX98; Sepcidin; Viradin

Latest Information Update: 04 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NexBio
  • Developer Ansun Biopharma
  • Class Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Viral haemorrhagic fevers
  • Discontinued Sepsis; Septic shock

Most Recent Events

  • 04 Aug 2015 Preclinical development is ongoing for bacterial infections and viral haemorrhagic fevers in USA
  • 04 Aug 2015 Discontinued for Septic shock in USA (IV)
  • 27 Jul 2015 Discontinued for Sepsis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top